¼¼°èÀÇ ºí¸°½ÃÅä(Blincyto) ½ÃÀå º¸°í¼­(2025³â) : ¿ªÇÐ, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, ½ÃÀå ÀλçÀÌÆ® ¹× ¿¹Ãø
Blincyto Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts
»óǰÄÚµå : 1763062
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,290,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,091,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,893,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºí¸°½ÃÅä ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â°£ °­ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ȯÀÚ Áß½É Ä¡·á ¸ðµ¨·ÎÀÇ Àüȯ, ÁÖ»çÁ¦ Ä¡·áÁ¦ÀÇ ÀÌ¿ë °¡´É¼º Áõ°¡, Á¦¾à ȸ»çÀÇ °ü½É Áõ°¡, »îÀÇ Áú °³¼±¿¡ ´ëÇÑ °ü½É Áõ°¡, ¼ºÀÎ ALL ¹ßº´·ü Áõ°¡¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ±â¼ú ¹ßÀüÀ» À§ÇÑ ¿¬±¸ ÀÚ±Ý Áö¿ø, ÀÌÁß Æ¯À̼º T¼¼Æ÷ °áÇÕÁ¦ÀÇ ÃâÇö, ¼¼Æ÷ Ä¡·áÀÇ ¹ßÀü, ȯÀÚ ¸ð´ÏÅ͸µ ±â¼úÀÇ Çâ»ó, Á¦Çü ±â¼úÀÇ °³¼± µîÀÌ ÀÖ½À´Ï´Ù.

¹éÇ÷º´ ¹ßº´·üÀÇ Áõ°¡´Â ºí¸°½ÃÅä ½ÃÀåÀÇ È®ÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °ñ¼ö µî Ç÷¾× »ý¼º Á¶Á÷¿¡¼­ ¹ß»ýÇÏ´Â ¾ÏÀÇ ÀÏÁ¾ÀÎ ¹éÇ÷º´Àº ºñÁ¤»óÀûÀÎ ¹éÇ÷±¸°¡ °úµµÇÏ°Ô »ý¼ºµÇ¾î Á¤»óÀûÀÎ Ç÷¾× ¼¼Æ÷ÀÇ ±â´ÉÀ» ¹æÇØÇÕ´Ï´Ù. ¹éÇ÷º´ ¹ßº´·üÀÇ Áõ°¡´Â Àα¸ °í·ÉÈ­, ȯ°æ ³ëÃâ, À¯ÀüÀû ¼ÒÀÎ, Áø´Ü ´É·Â Çâ»ó µîÀÇ ¿äÀΰú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ºí¸°½ÃÅä´Â ÀÌÁß Æ¯ÀÌ T¼¼Æ÷ °áÇÕÁ¦·Î¼­ ¹éÇ÷º´ Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ƯÈ÷ ±Þ¼º ¸²ÇÁ¸ð±¸ ¹éÇ÷º´(ALL) ȯÀÚÀÇ ¸é¿ª ü°è°¡ ¹éÇ÷º´ ¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ Á¦°ÅÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù ¹Ì±¹ ¾Ï Çùȸ´Â 2024³â ¹Ì±¹¿¡¼­ ¾à 6¸¸ 2,770°ÇÀÇ »õ·Î¿î ¹éÇ÷º´ »ç·Ê°¡ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹ÃøÇßÀ¸¸ç, ÀÌ´Â 2023³âÀÇ 5¸¸ 9,610°Ç¿¡¼­ Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ·Î ÀÎÇØ ¹éÇ÷º´ ¹ß»ý·üÀÇ Áõ°¡°¡ ºí¸°½ÃÅä ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÀÇ·áºñ ÁöÃâÀÇ Áõ°¡´Â ºí¸°½ÃÅä ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·áºñ ÁöÃâÀº °³ÀÎ °£È£, °øÁß º¸°Ç ÇÁ·Î±×·¥, º¸°Ç ÇàÁ¤À» Æ÷ÇÔÇÑ ÀÇ·á ¼­ºñ½º ¹× »óǰ¿¡ ´ëÇÑ ¸ðµç ÁöÃâÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÁöÃâÀº Àα¸ Áõ°¡, Àα¸ °í·ÉÈ­, ¼­ºñ½º ºñ¿ë »ó½Â, ¸¸¼º Áúȯ À¯º´·ü Áõ°¡, ÀÇ·á ±â¼úÀÇ ¹ßÀü°ú °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áºñ ÁöÃâÀÇ Áõ°¡´Â ºí¸°½ÃÅä¿Í °°Àº ÷´Ü ¾Ï Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±ÇÏ¿© ´õ ³ÐÀº äÅðú ´õ ³ªÀº ȯÀÚ °á°ú¸¦ ÃËÁøÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 5¿ù ¿µ±¹ ±¹°¡Åë°èû(Office for National Statistics)ÀÇ º¸°í¼­¿¡ µû¸£¸é, 2023³â ¿µ±¹ÀÇ ÀÇ·áºñ ÁöÃâÀº ¾à 3,630¾ï ´Þ·¯¿¡ ´ÞÇÏ¿© Àü³âµµ¿¡ ºñÇØ 5.6% Áõ°¡ÇßÀ¸¸ç, ÀÌ´Â 2022³âÀÇ 0.9% Áõ°¡À²À» ÈξÀ ¿ôµµ´Â ¼öÄ¡ÀÔ´Ï´Ù. °á°úÀûÀ¸·Î, ÀÇ·áºñ ÁöÃâÀÇ Áõ°¡´Â ºí¸°½ÃÅä ½ÃÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå¿¡¼­ÀÇ Á¦Ç° Ư¼º

Á¦4Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦5Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°, °æ±â ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦6Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦7Àå ¼¼°è ½ÃÀåÀÇ °¡°Ý ºÐ¼®°ú ¿¹Ãø

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­

Á¦9Àå ÀÓ»óÀûÀÀÁõ ¼¼°è ½ÃÀå ¿ªÇÐ

Á¦10Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦12Àå Áß±¹ ½ÃÀå

Á¦13Àå Àεµ ½ÃÀå

Á¦14Àå ÀϺ» ½ÃÀå

Á¦15Àå È£ÁÖ ½ÃÀå

Á¦16Àå Çѱ¹ ½ÃÀå

Á¦17Àå ¼­À¯·´ ½ÃÀå

Á¦18Àå ¿µ±¹ ½ÃÀå

Á¦19Àå µ¶ÀÏ ½ÃÀå

Á¦20Àå ÇÁ¶û½º ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ºÏ¹Ì ½ÃÀå

Á¦23Àå ¹Ì±¹ ½ÃÀå

Á¦24Àå ij³ª´Ù ½ÃÀå

Á¦25Àå ³²¹Ì ½ÃÀå

Á¦26Àå Áßµ¿ ½ÃÀå

Á¦27Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦28Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦29Àå ¼¼°è ½ÃÀå : ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

Á¦30Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦31Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦32Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦33Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦34Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Blincyto (blinatumomab) is a prescription medication designed for the treatment of specific blood cancers. As a bi-specific T-cell engager (BiTE) antibody construct, it operates by linking cancerous B-cells with T-cells (a type of immune cell), harnessing the immune system to identify and eliminate the cancerous B-cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of blincyto are prefilled and non-prefilled formulations. The prefilled option comes in ready-to-use syringes or vials, simplifying preparation and administration. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used to treat acute lymphoblastic leukemia and other hematological disorders. Key users include hospitals, clinics, and research institutions.

The blincyto market research report is one of a series of new reports from The Business Research Company that provides blincyto market statistics, including blincyto industry global market size, regional shares, competitors with a blincyto market share, detailed blincyto market segments, market trends and opportunities, and any further data you may need to thrive in the blincyto industry. This blincyto market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blincyto market size is expected to see strong growth in the next few years. It will grow to $1,022.1 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing shift towards patient-centric care models, increasing availability of injectable therapies, increasing interest from pharmaceutical companies, increasing focus on quality of life improvements, rising incidence of ALL in adults. Major trends in the forecast period include research funding for technological advancements, emergence of bispecific t-cell engagers, advancements in cell therapy, enhanced patient monitoring technologies, improved formulation techniques.

The growing incidence of leukemia is anticipated to drive the expansion of the Blincyto market. Leukemia, a type of cancer originating in blood-forming tissues like bone marrow, causes the overproduction of abnormal white blood cells, which disrupt normal blood cell function. The rise in leukemia cases is linked to factors such as an aging population, environmental exposures, genetic predispositions, and improved diagnostic capabilities. Blincyto plays a critical role in treating leukemia as a bispecific T-cell engager, helping the immune system target and eliminate leukemia cells, especially in patients with acute lymphoblastic leukemia (ALL). For example, in January 2024, the American Cancer Society projected approximately 62,770 new leukemia cases in the United States in 2024, an increase from 59,610 in 2023. As a result, the rising incidence of leukemia is fueling the growth of the Blincyto market.

An increase in healthcare spending is expected to support the growth of the Blincyto market. Healthcare spending encompasses all expenditures on health services and goods, including personal care, public health programs, and health administration. This spending is rising due to factors such as population growth, aging demographics, rising service costs, higher chronic illness prevalence, and advancements in medical technology. The rise in healthcare spending improves access to advanced cancer treatments like Blincyto, facilitating wider adoption and better patient outcomes. For instance, in May 2024, a report from the Office for National Statistics in the UK revealed that healthcare expenditure in the UK reached around $363 billion in 2023, representing a 5.6% increase from the previous year, well above the 0.9% increase in 2022. Consequently, higher healthcare spending is driving the Blincyto market.

A key trend in the Blincyto market is the focus on developing innovative therapies, including immuno-oncology treatments, to target and destroy cancer cells. Immuno-oncology therapies use the body's immune system to recognize and eliminate cancer cells. For example, in June 2024, Amgen Inc., a U.S.-based biotechnology company, received FDA approval for Blincyto (blinatumomab) to treat CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in both adult and pediatric patients, regardless of the presence of measurable residual disease (MRD). Blincyto is a bispecific T-cell engager (BiTE) that binds to CD19 on B-cell tumors and CD3 on T-cells, guiding T-cells to target and destroy cancer cells.

Key player operating in the blincyto market is Amgen Inc.

North America was the largest region in the Blincyto market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blincyto report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the blincyto market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The blincyto market consists of sales of oncology medications, biosimilars, immunotherapy drugs, anti-inflammatory medications and hematology medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blincyto Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on blincyto market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for blincyto ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blincyto market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Blincyto Market Characteristics

3. Blincyto Market Biologic Drug Characteristics

4. Blincyto Market Trends And Strategies

5. Blincyto Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Blincyto Growth Analysis And Strategic Analysis Framework

7. Global Blincyto Market Pricing Analysis & Forecasts

8. Blincyto Market Segmentation

9. Global Blincyto Market Epidemiology Of Clinical Indications

10. Blincyto Market Regional And Country Analysis

11. Asia-Pacific Blincyto Market

12. China Blincyto Market

13. India Blincyto Market

14. Japan Blincyto Market

15. Australia Blincyto Market

16. South Korea Blincyto Market

17. Western Europe Blincyto Market

18. UK Blincyto Market

19. Germany Blincyto Market

20. France Blincyto Market

21. Eastern Europe Blincyto Market

22. North America Blincyto Market

23. USA Blincyto Market

24. Canada Blincyto Market

25. South America Blincyto Market

26. Middle East Blincyto Market

27. Africa Blincyto Market

28. Blincyto Market Competitive Landscape And Company Profiles

29. Global Blincyto Market Pipeline Analysis

30. Global Blincyto Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Blincyto Market

32. Recent Developments In The Blincyto Market

33. Blincyto Market High Potential Countries, Segments and Strategies

34. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â